Encouraging most importantly because clearly the p
Post# of 553
have been receptive in the 1/28 meeting to have encouraged the company to submit their follow up answers. "With these matters resolved, the company expects to submit to the FDA its additional responses addressing all preclinical and clinical comments, in early February." PROGRESS!
$5-$10+

